Cure51
Founded 2021 · 61 employees on LinkedIn · 4 known investors
Cure51 is a cancer research company that decodes the biology of exceptional cancer survivors ("cancer outliers") using molecular profiling and computational biology, collecting patient data on its Patient Profile Platform. It works with cancer centers and clinical partners as part of the Rosalind Study to advance cancer research.
Founders & leadership
Cure51 was founded in 2021 by Paloma Cejas and Rémy Nicolle.
PC
Paloma CejasinFounder, Head of Translational Research
RN
Rémy NicolleFounder, Senior Advisor Computational Biology
Investors · 4
Funding
SEC filings, press & company announcements- Undisclosed amountseed roundMar 2024 · 4 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Cure51 do?
- Cure51 is a cancer research company that decodes the biology of exceptional cancer survivors ("cancer outliers") using molecular profiling and computational biology, collecting patient data on its Patient Profile Platform. It works with cancer centers and clinical partners as part of the Rosalind Study to advance cancer research.
- Who founded Cure51?
- Cure51 was founded by Paloma Cejas, Rémy Nicolle in 2021.
- Who are Cure51's investors?
- Cure51's investors include Hitachi Ventures, Kima Ventures, LifeX Ventures, Sofinnova Partners.